BPMC
Price
$127.90
Change
-$0.20 (-0.16%)
Updated
Jun 5 closing price
Capitalization
8.26B
54 days until earnings call
IDYA
Price
$21.63
Change
+$0.53 (+2.51%)
Updated
Jun 6, 10:33 AM (EDT)
Capitalization
1.85B
67 days until earnings call
Interact to see
Advertisement

BPMC vs IDYA

Header iconBPMC vs IDYA Comparison
Open Charts BPMC vs IDYABanner chart's image
Blueprint Medicines
Price$127.90
Change-$0.20 (-0.16%)
Volume$4.45M
Capitalization8.26B
IDEAYA Biosciences
Price$21.63
Change+$0.53 (+2.51%)
Volume$127
Capitalization1.85B
BPMC vs IDYA Comparison Chart
Loading...
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BPMC vs. IDYA commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BPMC is a Buy and IDYA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (BPMC: $127.92 vs. IDYA: $21.08)
Brand notoriety: BPMC and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BPMC: 171% vs. IDYA: 45%
Market capitalization -- BPMC: $8.26B vs. IDYA: $1.85B
BPMC [@Biotechnology] is valued at $8.26B. IDYA’s [@Biotechnology] market capitalization is $1.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BPMC’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • BPMC’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than BPMC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BPMC’s TA Score shows that 6 TA indicator(s) are bullish while IDYA’s TA Score has 6 bullish TA indicator(s).

  • BPMC’s TA Score: 6 bullish, 4 bearish.
  • IDYA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both BPMC and IDYA are a good buy in the short-term.

Price Growth

BPMC (@Biotechnology) experienced а +24.12% price change this week, while IDYA (@Biotechnology) price change was +5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

BPMC is expected to report earnings on Jul 30, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BPMC($8.26B) has a higher market cap than IDYA($1.85B). BPMC YTD gains are higher at: 46.664 vs. IDYA (-17.977). BPMC has higher annual earnings (EBITDA): -66.42M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. BPMC (576M). IDYA has less debt than BPMC: IDYA (26M) vs BPMC (467M). BPMC has higher revenues than IDYA: BPMC (562M) vs IDYA (7M).
BPMCIDYABPMC / IDYA
Capitalization8.26B1.85B448%
EBITDA-66.42M-356.46M19%
Gain YTD46.664-17.977-260%
P/E RatioN/AN/A-
Revenue562M7M8,029%
Total Cash576M693M83%
Total Debt467M26M1,796%
FUNDAMENTALS RATINGS
BPMC vs IDYA: Fundamental Ratings
BPMC
IDYA
OUTLOOK RATING
1..100
7717
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
5166
SMR RATING
1..100
9445
PRICE GROWTH RATING
1..100
3861
P/E GROWTH RATING
1..100
62100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is in the same range as BPMC (82) in the Biotechnology industry. This means that IDYA’s stock grew similarly to BPMC’s over the last 12 months.

BPMC's Profit vs Risk Rating (51) in the Biotechnology industry is in the same range as IDYA (66) in the null industry. This means that BPMC’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's SMR Rating (45) in the null industry is somewhat better than the same rating for BPMC (94) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than BPMC’s over the last 12 months.

BPMC's Price Growth Rating (38) in the Biotechnology industry is in the same range as IDYA (61) in the null industry. This means that BPMC’s stock grew similarly to IDYA’s over the last 12 months.

BPMC's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for IDYA (100) in the null industry. This means that BPMC’s stock grew somewhat faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BPMCIDYA
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 22 days ago
73%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 10 days ago
73%
Bearish Trend 1 day ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
70%
Aroon
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VMGMX117.35N/A
N/A
Vanguard Mid-Cap Growth Index Admiral
ARSZX9.81N/A
N/A
AMG River Road Small-Mid Cap Value Z
COSAX11.77N/A
N/A
Columbia Overseas Core A
SBASX11.97N/A
N/A
Segall Bryant &Hamill Small Cap Cre Ins
CGIOX47.08-0.19
-0.40%
Calamos Growth and Income R6

BPMC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with LYRA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPMC
1D Price
Change %
BPMC100%
-0.14%
LYRA - BPMC
44%
Loosely correlated
+9.07%
ORIC - BPMC
42%
Loosely correlated
+0.88%
INSM - BPMC
42%
Loosely correlated
-1.29%
ARQT - BPMC
42%
Loosely correlated
+1.81%
AXON - BPMC
41%
Loosely correlated
+1.08%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with CGON. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.09%
CGON - IDYA
60%
Loosely correlated
+0.23%
IMNM - IDYA
59%
Loosely correlated
+1.16%
CRNX - IDYA
56%
Loosely correlated
+0.59%
ETNB - IDYA
55%
Loosely correlated
-0.99%
KRYS - IDYA
55%
Loosely correlated
+0.53%
More